Wednesday, March 21, 2012

Dykenesia Trial Yields Promising Results for Patients

A note from the Michael J. Fox Foundation:

Today, good news in the search for a treatment for dyskinesia, the uncontrollable movements that are so often a disabling side effect of Parkinson's disease medication.
Swiss biotech and Michael J. Fox Foundation awardee Addex Therapeutics has announced positive results from a phase 2 clinical study of their drug candidate dipraglurant, which is being tested as a therapy to be taken in conjunction with levodopa (the gold standard for treating PD). By targeting the brain's glutamate system, the hope is that the dipraglurant would allow patients taking levodopa to experience better "on" times without dyskinesia.

Dyskinesia is of course, a real roadblock to the long term treatment of PD. Finding a successful treatment to limit this side effect could have major implications for those living with PD today. While such a therapy is still a ways off, the Addex results represent an important next step in driving a potential drug for dyskinesia to market.

To learn more, read the Foundation's News in Context interview with Bill Langston, MD, scientific director and chief executive officer of The Parkinson's Institute in Sunnyvale, California, and staff scientists Audrey Dufour, PhD and Jamie Eberling, PhD. 

Wednesday, March 14, 2012

Parkinson's Disease Stopped in Animal Model



KINGSTON, N.J., March 12, 2012 /PRNewswire-USNewswire/ -- Martin Tuchman, Chairman of the Parkinson's Unity Walk and The Parkinson Alliance, announced today that funds raised through the Parkinson's community helped support the research that led to this breakthrough.

Investigators at David Geffen School of Medicine at UCLA have reported the ability of a novel molecule CLRO1 (called a "molecular tweezer") to inhibit toxicity due to abnormal aggregation of a protein synuclein. Synuclein is widely believed to cause neuron death in human Parkinson's disease due to its tendency to form abnormal aggregations within neurons. The investigators found that CLRO1 both prevented and broke up a-synuclein aggregates.

The research, "A Novel 'Molecular Tweezer' Inhibitor of a-Synuclein Neurotoxicity in Vitro and in Vivo" appears in the current online edition (2012 February 29) of the journal Neurotherapeutics.

A great deal of the money raised by the Parkinson's organizations goes to fund ground breaking research; a level of pride is felt by the community that these dollars helped to fund this extraordinary and most promising research.

Dr. Robert E. Burke, Professor of Neurology and Pathology at Columbia University Medical Center and member of the Board of Directors of the Parkinson's Unity Walk, who did not participate in the research, stated: "This is a highly novel and promising approach aimed directly at a principal culprit in human Parkinson's disease, the protein synuclein."

About The Parkinson Alliance

The Parkinson Alliance is a Kingston, NJ-based national non-profit organization dedicated to raising funds to help finance the most promising research to find the cause and cure for Parkinson's disease. It is the umbrella organization for Team Parkinson, and its signature event, the annual Parkinson's Unity Walk, to take place on Saturday, April 28 in New York's Central Park. For more information, visit

Carol Walton, Chief Executive Officer, The Parkinson Alliance

Parkinson Alliance

Web site:

Copyright PRNewswire-USNewswire 2012

Monday, March 5, 2012

New Lyme Book by PJ Langhoff


Lyme, AIDS, Morgellon's Caused by GM (genetically modified) toxic wastes?

Nuclear, agricultural, and industrial wastes may have led to human diseases often denied by public health experts

A provocative expose by Midwest author PJ Langhoff suggests that Lyme disease, HIV/AIDS, Morgellon's, and other infections including those with 'no known cause' may have important ties to genetic engineering "accidents" and toxic pollutants. The new book, "The Fourth Monkey: An Untold History of the Lyme Disease Epidemic" describes the hidden history of today's most controversial illnesses, and their likely connections to highly profitable industries.

The book examines disease links to contaminated wastewaters and soils; and the implications of tainted vaccines and genetically modified (GM) microbes, insects, plants, and industrial biocides. Can biotech tools lead to human diseases including the reactivation of sleeping viruses? Are insects transmitting lab-made formulas thought "safe," and widely used by agriculture, nuclear, mining, plastics, or other industries?

Public health officials were tracking important diseases on several continents since the 1950s. However Langhoff's book presents a far less public side to academic and industrial health and science that may be negatively impacting millions of people around the world. Now available in paperback and handheld versions at:

Allegory Press, LLC
PO Box 444
Hustisford, Wisconsin, 53034 USA